Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - A placebo-controlled double-blind study

European Journal of Clinical Nutrition

Volumn 58, Issue 3, 2004, Pages 467-473

  Hirayama, S ^a   Hamazaki, T ^b   Terasawa, K ^b  

^a Kurashiki City College   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Attention deficit; Complimentary and alternative methods; Continuous performance; Docosahexaenoic acid; Fish oil; Hyperactivity disorder; Intervention study; Visual memory

Indexed keywords

CARBAMAZEPINE; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; FLUVOXAMINE; METHYLPHENIDATE; PLACEBO; RISPERIDONE; SULPIRIDE;

AGGRESSION; ANALYTICAL ERROR; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY MEMORY; BREAD; CALCULATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; FOOD INTAKE; HUMAN; IMPULSIVENESS; MALE; MILK; SHORT TERM MEMORY; SYMPTOMATOLOGY; TASK PERFORMANCE; TIME; VISION; VISUAL MEMORY; VISUOMOTOR COORDINATION;

AGGRESSION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD BEHAVIOR; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; FISH OILS; HUMANS; MALE; MEMORY; PLACEBOS; TREATMENT OUTCOME;

GLYCINE MAX;

EID: 1842527941     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1601830     Document Type: Article

References (34)

1. Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam F, Klimmek R & Forth W (2003): Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol. Int. 23, 27-36.
2. Aman MG, Mitchell EA & Turbott SH (1987): The effects of essential fatty acid supplementation by Efamol in hyperactive children. J. Abnorm. Child Psychol. 15, 75-90.
3. Arnold LE (1999): Treatment alternatives for attention deficit hyperactivity disorder. J. Attention Disord. 3, 30-48.
4. Beery KE (1967): Developmental Test of Visual-Motor: Administration and Scoring Manual. Chicago: Follett Publishing Co.
5. Biederman J & Spencer T (1999): Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46, 1234-1242.
6. Brue AW & Oakland TD. (2002): Alternative treatments for attention-deficit/hyperactivity disorder: Does evidence support their use? Altern. Ther. Health Med. 8, 68-70.
7. Burgess JR (1998): Attention deficit hyperactivity disorder, observational and interventional studies. NIH Workshop on Omega-3 Essential Fatty Acids and Psychiatric Disorders. Abstract book 22.
8. Carter CM, Urbanowicz M, Hemsley R, Mantilla L, Strobel S, Graham PJ & Taylor E (1993): Effects of a few food diet in attention deficit disorder. Arch. Dis. Childhood 69, 564-568.
9. Cooper JR, Bloom FE & Roth RH (2003): Noradrenaline and adrenaline. In Biochemical Basis of Neuropharmacology, 8th Edition, pp 181-224. New York: Oxford University Press.
10. Corkum PV & Siegel LS (1993): Is the continuous performance task a valuable research tool for use with children with attention-deficit hyperactivity disorder? J. Child Psychol. Psychiatry. 29, 1217-1239.
11. Frostig M, Lefever DW & Whittlesey JRB (1966): Administration and Scoring Manual for the Marianne Frostig Developmental Test of Visual Perception. Palo Alto: Consulting Psychologists Press.
12. Gesch CB, Hammond SM, Hampson SE, Eves A & Crowder MJ (2002): Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Br. J. Psychiatry 181, 22-28.
13. Goldman LS, Genel M, Bezman RJ & Slanetz PJ (1998): Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279, 1100-1107.
14. Haller J, Makara GB & Kruk MR (1998): Catecholaminergic involvement in the control of aggression: Hormones, the peripheral sympathetic, and central noradrenergic systems. Neurosci. Biobehav. Rev. 22, 85-97.
15. Hamazaki K, Itomura M, Huan M, Nishizawa H, Watanabe S, Hamazaki T, Sawazaki S, Terasawa K, Nakajima S, Terano T, Hata Y & Fujishiro S (2003): N-3 long chain fatty acids decrease serum levels of triglycerides and remnant-like particle-cholesterol in humans. Lipids. 38, 353-358.
16. Hamazaki T & Okuyama H (2003): The Japan Society for Lipid Nutrition recommends to reduce the intake of linoleic acid. A review and critique of the scientific evidence. In Omega-6/Omega-3 Essential Fatty Acid Ratio: The Scientific Evidence, Volume eds AP Simopoulos & LG Cleland. World Review of Nutrition and Dietetics, Vol 92, pp 109-132. Basel: Karger.
17. Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, Yazawa K, Kuwamori T & Kobayashi M (1996): The effect of docosahexaenoic acid on aggression in young adults, a placebo-controlled double-blind study. J. Clin. Invest. 97, 1129-1133.
18. Hamazaki T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, Nagasawa T & Watanabe S (2002): The effect of docosahexaenoic acid on aggression in elderly Thai subjects - a placebo-controlled double-blind study. Nutr. Neurosci. 6, 37-41.
19. Hulme C & Sackenzie S (1992): Working memory: structure and function. In Working Memory and Severe Learning Difficulties, pp 17-37. Hillsdale: Lawrence Erlbaum Associates Publishers.
20. Itomura M, Sawazaki S, Terasawa K, Hamazaki K, Watanabe S & Hamazaki T (2002): Aggression and the fatty acid composition of red blood cells (RBCs) in schoolchildren. 5th Congress of the International Society for the Study of Fatty Acids and Lipids, Montreal. Abstract book 128.
21. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF & Puryear LJ (2003): A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 160, 996-998.
22. Miller GA (1956): The magical number seven plus or minus two: some limits on our capacity for processing information. Psychol. Rev. 63, 81-97.
23. Mitchell EA, Aman MG, Turbott SH & Manku M (1987): Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin. Pediatr. 26, 406-411.
24. Nemets B, Stahl Z & Belmaker RH (2002): Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 159, 477-479.
25. Peet M & Horrobin DF (2002): A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59, 913-919.
26. Puri BK & Richardson AD (2000): The effects of olive oil on ω3 fatty acids and mood disorder. Arch. Gen. Psychiatry 57, 715.
27. Rapport MD, Denney C, DuPaul GJ & Gardner MJ (1994): Attention deficit disorder and methylphenidate: Normalization rates, clinical effectiveness, and response prediction in 76 children. J. Am. Acad. Child Adolesc. Psychiatry 33, 882-893.
28. Richardson AJ & Puri BK (2002): A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26, 233-239.
29. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI & Partilla JS (2001): Amphetamine-type central nervous system stimulants release noradrenaline more potently than they release dopamine and serotonin. Synapse 39, 32-41.
30. Sawazaki S, Hamazaki T, Yazawa K & Kobayashi M (1999): The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: A double-blind placebo-controlled study. J. Nutr. Sci. Vitaminol. 45, 655-665.
31. Stevens LJ, Zentall SS, Deck JL, Abate ME, Watkins BA, Lipp SR & Burgess JR (1995): Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 62, 761-768.
32. Terano T, Hirai A, Tamura Y, Kumagai A & Yoshida S (1987). Effect of dietary supplementation of highly purified eicosapentaenoic acid and docosahexaenoic acid on arachidonic acid metabolism in leukocytes and leukocyte function in healthy volunteers. Adv. Prostaglandin Thromboxane Leukotriene Res. 17B, 880 885.
33. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC & Heird WC (2001): A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr 139, 189-196.
34. Wilens TE, Biederman J & Spencer TJ (2002): Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. 53, 113-131.